Entera Stock Based Compensation from 2010 to 2024
ENTX Stock | USD 2.16 0.07 3.35% |
Stock Based Compensation | First Reported 2016-09-30 | Previous Quarter 383 K | Current Value 318 K | Quarterly Volatility 421.1 K |
Check Entera Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Entera main balance sheet or income statement drivers, such as Depreciation And Amortization of 97.3 K, Interest Expense of 31.4 M or Selling General Administrative of 5.2 M, as well as many exotic indicators such as Price To Sales Ratio of 79.86, Dividend Yield of 0.0 or PTB Ratio of 1.76. Entera financial statements analysis is a perfect complement when working with Entera Bio Valuation or Volatility modules.
Entera | Stock Based Compensation |
Latest Entera Bio's Stock Based Compensation Growth Pattern
Below is the plot of the Stock Based Compensation of Entera Bio over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Entera Bio's Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Entera Bio's overall financial position and show how it may be relating to other accounts over time.
Stock Based Compensation | 10 Years Trend |
|
Stock Based Compensation |
Timeline |
Entera Stock Based Compensation Regression Statistics
Arithmetic Mean | 1,330,633 | |
Geometric Mean | 941,052 | |
Coefficient Of Variation | 90.10 | |
Mean Deviation | 842,009 | |
Median | 1,233,000 | |
Standard Deviation | 1,198,909 | |
Sample Variance | 1.4T | |
Range | 4.5M | |
R-Value | 0.51 | |
Mean Square Error | 1.1T | |
R-Squared | 0.26 | |
Significance | 0.05 | |
Slope | 136,302 | |
Total Sum of Squares | 20.1T |
Entera Stock Based Compensation History
Other Fundumenentals of Entera Bio
Entera Bio Stock Based Compensation component correlations
Click cells to compare fundamentals
About Entera Bio Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Entera Bio income statement, its balance sheet, and the statement of cash flows. Entera Bio investors use historical funamental indicators, such as Entera Bio's Stock Based Compensation, to determine how well the company is positioned to perform in the future. Although Entera Bio investors may use each financial statement separately, they are all related. The changes in Entera Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Entera Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Entera Bio Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Entera Bio. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Stock Based Compensation | 1.7 M | 2 M | |
Stock Based Compensation To Revenue | 15.09 | 15.85 |
Pair Trading with Entera Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Entera Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entera Bio will appreciate offsetting losses from the drop in the long position's value.Moving together with Entera Stock
0.64 | ELVN | Enliven Therapeutics Trending | PairCorr |
Moving against Entera Stock
0.9 | IMCR | Immunocore Holdings Financial Report 8th of May 2024 | PairCorr |
0.87 | LGVN | Longeveron LLC Earnings Call This Week | PairCorr |
0.8 | TXG | 10X Genomics | PairCorr |
0.8 | IMRX | Immuneering Corp Earnings Call This Week | PairCorr |
0.77 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to Entera Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Entera Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Entera Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Entera Bio to buy it.
The correlation of Entera Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entera Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entera Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Entera Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Entera Bio Correlation against competitors. For more information on how to buy Entera Stock please use our How to Invest in Entera Bio guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Entera Stock analysis
When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
CEOs Directory Screen CEOs from public companies around the world |
Is Entera Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entera Bio. If investors know Entera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entera Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.31) | Quarterly Revenue Growth (0.92) | Return On Assets (0.45) | Return On Equity (0.80) |
The market value of Entera Bio is measured differently than its book value, which is the value of Entera that is recorded on the company's balance sheet. Investors also form their own opinion of Entera Bio's value that differs from its market value or its book value, called intrinsic value, which is Entera Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entera Bio's market value can be influenced by many factors that don't directly affect Entera Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entera Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Entera Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entera Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.